252 related articles for article (PubMed ID: 11834876)
21. Effects of nitric oxide synthase inhibition and endothelin ETA receptor blockade on haemodynamics in hypertensive rats.
Granstam SO; Lind L; Granstam E; Fellström B
Clin Exp Pharmacol Physiol; 1998 Sep; 25(9):693-701. PubMed ID: 9750958
[TBL] [Abstract][Full Text] [Related]
22. Nitric oxide synthesis inhibition does not impair water immersion-induced renal vasodilation in humans.
Dijkhorst-Oei LT; Boer P; Rabelink TJ; Koomans HA
J Am Soc Nephrol; 2000 Jul; 11(7):1293-1302. PubMed ID: 10864586
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans.
Mayer BX; Mensik C; Krishnaswami S; Derendorf H; Eichler HG; Schmetterer L; Wolzt M
Br J Clin Pharmacol; 1999 May; 47(5):539-44. PubMed ID: 10336578
[TBL] [Abstract][Full Text] [Related]
24. The ocular hemodynamic response to nitric oxide synthase inhibition is unaltered in patients with early type I diabetes.
Dorner GT; Garhöfer G; Selenko N; Fasching P; Bayerle-Eder M; Schmetterer L; Wolzt M
Graefes Arch Clin Exp Ophthalmol; 2003 Aug; 241(8):619-24. PubMed ID: 12836035
[TBL] [Abstract][Full Text] [Related]
25. Systemic NO synthase inhibition blunts the chronotropic, but not the inotropic response to isoprenaline in man.
Schmetterer L; Dallinger S; Polak K; Eichler HG; Wolzt M
Nitric Oxide; 1999 Jun; 3(3):209-15. PubMed ID: 10442852
[TBL] [Abstract][Full Text] [Related]
26. Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.
Mose FH; Jensen JM; Therwani S; Mortensen J; Hansen AB; Bech JN; Pedersen EB
Br J Clin Pharmacol; 2015 Sep; 80(3):425-35. PubMed ID: 25778445
[TBL] [Abstract][Full Text] [Related]
27. Physiological role of nitric oxide in regulation of renal function in humans.
Haynes WG; Hand MF; Dockrell ME; Eadington DW; Lee MR; Hussein Z; Benjamin N; Webb DJ
Am J Physiol; 1997 Mar; 272(3 Pt 2):F364-71. PubMed ID: 9087680
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide-endothelin-1 interaction in humans.
Ahlborg G; Lundberg JM
J Appl Physiol (1985); 1997 May; 82(5):1593-600. PubMed ID: 9134909
[TBL] [Abstract][Full Text] [Related]
29. The systemic and renal response to NO inhibition is not modified by angiotensin-II-receptor blockade in healthy humans.
Bech JN; Svendsen KB; Nielsen CB; Pedersen EB
Nephrol Dial Transplant; 1999 Mar; 14(3):641-7. PubMed ID: 10193813
[TBL] [Abstract][Full Text] [Related]
30. Intracarotid infusion of the nitric oxide synthase inhibitor, L-NMMA, modestly decreases cerebral blood flow in human subjects.
Joshi S; Young WL; Duong DH; Ostapkovich ND; Aagaard BD; Hashimoto T; Pile-Spellman J
Anesthesiology; 2000 Sep; 93(3):699-707. PubMed ID: 10969303
[TBL] [Abstract][Full Text] [Related]
31. Contribution of central nitric oxide to the regulation of blood pressure and sodium balance in DOCA-salt hypertension.
Seto S; Nagao S; Ozeki S; Tetsuo H; Akahoshi M; Yano K
J Cardiovasc Pharmacol; 2006 May; 47(5):680-5. PubMed ID: 16775508
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of nitric oxide synthase modulation on porcine systemic and pulmonary circulation in vivo.
Dahm P; Thörne J; Zoucas E; Mårtensson L; Myhre E; Blomquist S
Crit Care Med; 1997 Feb; 25(2):280-5. PubMed ID: 9034265
[TBL] [Abstract][Full Text] [Related]
33. Effect of nos inhibition on retinal arterial and capillary circulation in early arterial hypertension.
Michelson G; Wärntges S; Harazny J; Oehmer S; Delles C; Schmieder RE
Retina; 2006 Apr; 26(4):437-44. PubMed ID: 16603964
[TBL] [Abstract][Full Text] [Related]
34. Effects of a nitric oxide synthase inhibitor in humans with septic shock.
Petros A; Lamb G; Leone A; Moncada S; Bennett D; Vallance P
Cardiovasc Res; 1994 Jan; 28(1):34-9. PubMed ID: 7509259
[TBL] [Abstract][Full Text] [Related]
35. Haemodynamic effects of inhibition of nitric oxide synthase and of L-arginine at rest and during exercise.
Brett SE; Cockcroft JR; Mant TG; Ritter JM; Chowienczyk PJ
J Hypertens; 1998 Apr; 16(4):429-35. PubMed ID: 9797188
[TBL] [Abstract][Full Text] [Related]
36. Rapid nongenomic effects of aldosterone on the renal vasculature in humans.
Schmidt BM; Sammer U; Fleischmann I; Schlaich M; Delles C; Schmieder RE
Hypertension; 2006 Apr; 47(4):650-5. PubMed ID: 16520409
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide synthase inhibition versus norepinephrine for the treatment of hyperdynamic sepsis in sheep.
Booke M; Hinder F; McGuire R; Traber LD; Traber DL
Crit Care Med; 1996 May; 24(5):835-44. PubMed ID: 8706462
[TBL] [Abstract][Full Text] [Related]
38. Role of angiotensin II in L-NAME-induced systemic and renal hemodynamic effects in hydrochlorothiazide-pretreated hypertensive subjects.
van der Linde NA; van den Meiracker AH; Boomsma F
J Hypertens; 2003 Feb; 21(2):345-51. PubMed ID: 12569265
[TBL] [Abstract][Full Text] [Related]
39. Nitric oxide-angiotensin II interactions and renal hemodynamic function in patients with uncomplicated type 1 diabetes.
Montanari A; Pelà G; Musiari L; Crocamo A; Boeti L; Cabassi A; Biggi A; Cherney DZ
Am J Physiol Renal Physiol; 2013 Jul; 305(1):F42-51. PubMed ID: 23657857
[TBL] [Abstract][Full Text] [Related]
40. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
Tran D; Lowy A; Howes JB; Howes LG
Diabetes Obes Metab; 2005 May; 7(3):273-81. PubMed ID: 15811145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
